Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Bristol Myers Squibb Company stock logo
BMY
Bristol Myers Squibb
$57.04
+0.5%
$58.74
$42.52
$62.89
$116.48B0.2612.31 million shs10.73 million shs
GSK PLC Sponsored ADR stock logo
GSK
GSK
$49.66
-2.5%
$54.47
$35.45
$61.69
$100.78B0.385.07 million shs3.91 million shs
ImmunoGen, Inc. stock logo
IMGN
ImmunoGen
$31.23
$31.23
$3.61
$31.25
$8.32B1.188.78 million shsN/A
Iovance Biotherapeutics, Inc. stock logo
IOVA
Iovance Biotherapeutics
$3.45
-2.0%
$3.79
$1.64
$5.63
$1.54B0.6915.35 million shs7.59 million shs
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$1,005.20
-0.1%
$939.86
$623.78
$1,133.95
$946.63B0.483.20 million shs2.77 million shs
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
$44.71
-2.4%
$39.61
$35.12
$81.44
$199.63B0.7721.76 million shs16.35 million shs
5G Stocks: The Path Forward is Profitable Cover

Click the link to see MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Bristol Myers Squibb Company stock logo
BMY
Bristol Myers Squibb
+0.64%+1.03%-2.28%-6.39%+28.83%
GSK PLC Sponsored ADR stock logo
GSK
GSK
-0.07%+0.84%-13.99%-13.62%+40.43%
ImmunoGen, Inc. stock logo
IMGN
ImmunoGen
0.00%0.00%0.00%0.00%0.00%
Iovance Biotherapeutics, Inc. stock logo
IOVA
Iovance Biotherapeutics
-3.83%-0.85%-3.30%+36.70%+106.45%
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
-0.80%+3.28%+9.10%-3.20%+40.58%
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
-2.76%+0.10%+16.51%-7.60%-28.76%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Bristol Myers Squibb Company stock logo
BMY
Bristol Myers Squibb
$57.04
+0.5%
$58.74
$42.52
$62.89
$116.48B0.2612.31 million shs10.73 million shs
GSK PLC Sponsored ADR stock logo
GSK
GSK
$49.66
-2.5%
$54.47
$35.45
$61.69
$100.78B0.385.07 million shs3.91 million shs
ImmunoGen, Inc. stock logo
IMGN
ImmunoGen
$31.23
$31.23
$3.61
$31.25
$8.32B1.188.78 million shsN/A
Iovance Biotherapeutics, Inc. stock logo
IOVA
Iovance Biotherapeutics
$3.45
-2.0%
$3.79
$1.64
$5.63
$1.54B0.6915.35 million shs7.59 million shs
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$1,005.20
-0.1%
$939.86
$623.78
$1,133.95
$946.63B0.483.20 million shs2.77 million shs
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
$44.71
-2.4%
$39.61
$35.12
$81.44
$199.63B0.7721.76 million shs16.35 million shs
5G Stocks: The Path Forward is Profitable Cover

Click the link to see MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Bristol Myers Squibb Company stock logo
BMY
Bristol Myers Squibb
+0.64%+1.03%-2.28%-6.39%+28.83%
GSK PLC Sponsored ADR stock logo
GSK
GSK
-0.07%+0.84%-13.99%-13.62%+40.43%
ImmunoGen, Inc. stock logo
IMGN
ImmunoGen
0.00%0.00%0.00%0.00%0.00%
Iovance Biotherapeutics, Inc. stock logo
IOVA
Iovance Biotherapeutics
-3.83%-0.85%-3.30%+36.70%+106.45%
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
-0.80%+3.28%+9.10%-3.20%+40.58%
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
-2.76%+0.10%+16.51%-7.60%-28.76%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Bristol Myers Squibb Company stock logo
BMY
Bristol Myers Squibb
2.37
Hold$61.317.49% Upside
GSK PLC Sponsored ADR stock logo
GSK
GSK
1.90
Reduce$53.006.72% Upside
ImmunoGen, Inc. stock logo
IMGN
ImmunoGen
0.00
N/AN/AN/A
Iovance Biotherapeutics, Inc. stock logo
IOVA
Iovance Biotherapeutics
2.30
Hold$8.43144.31% Upside
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
2.87
Moderate Buy$1,218.3321.20% Upside
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
2.13
Hold$65.5646.64% Upside

Current Analyst Ratings Breakdown

Latest LLY, NVO, IMGN, GSK, BMY, and IOVA Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/12/2026
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
Reiterated RatingNeutral
5/7/2026
Iovance Biotherapeutics, Inc. stock logo
IOVA
Iovance Biotherapeutics
Lower Price TargetBuy$16.00 ➝ $14.00
5/7/2026
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
Boost Price Target$880.00 ➝ $900.00
5/5/2026
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
Reiterated RatingBuy$1,183.00
5/4/2026
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
UpgradeBuy (B-)Buy (B)
5/4/2026
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
Reiterated RatingOutperform$1,325.00
5/4/2026
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
Boost Price TargetOverweight$1,350.00 ➝ $1,400.00
5/1/2026
GSK PLC Sponsored ADR stock logo
GSK
GSK
UpgradeHold (C+)Buy (B)
5/1/2026
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
Reiterated RatingOverweight$1,344.00
5/1/2026
Bristol Myers Squibb Company stock logo
BMY
Bristol Myers Squibb
Reiterated RatingNeutral
5/1/2026
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
Reiterated RatingOutperform
(Data available from 5/15/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Bristol Myers Squibb Company stock logo
BMY
Bristol Myers Squibb
$48.19B2.42$8.23 per share6.93$9.84 per share5.80
GSK PLC Sponsored ADR stock logo
GSK
GSK
$43.07B2.34$5.85 per share8.49$11.57 per share4.29
ImmunoGen, Inc. stock logo
IMGN
ImmunoGen
$287.61M28.91N/AN/A$0.71 per share43.99
Iovance Biotherapeutics, Inc. stock logo
IOVA
Iovance Biotherapeutics
$263.50M5.85N/AN/A$1.62 per share2.13
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$65.18B14.52$24.87 per share40.41$33.13 per share30.34
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
$46.80B4.27$4.45 per share10.04$7.12 per share6.28
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Bristol Myers Squibb Company stock logo
BMY
Bristol Myers Squibb
$7.05B$3.5616.029.430.1615.01%64.87%13.16%7/30/2026 (Estimated)
GSK PLC Sponsored ADR stock logo
GSK
GSK
$7.54B$3.8512.919.662.6017.82%44.28%11.49%7/29/2026 (Estimated)
ImmunoGen, Inc. stock logo
IMGN
ImmunoGen
-$222.93M-$0.31N/A84.41N/A-25.56%-22.11%-13.53%N/A
Iovance Biotherapeutics, Inc. stock logo
IOVA
Iovance Biotherapeutics
-$390.98M-$0.95N/AN/AN/A-123.92%-50.17%-38.77%N/A
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$20.64B$28.1535.7122.711.1134.98%105.77%23.76%N/A
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
$15.51B$4.2610.5013.004.1937.23%63.31%22.19%N/A

Latest LLY, NVO, IMGN, GSK, BMY, and IOVA Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/7/2026Q1 2026
Iovance Biotherapeutics, Inc. stock logo
IOVA
Iovance Biotherapeutics
-$0.19-$0.19N/A-$0.19$77.84 million$71.43 million
5/6/2026Q1 2026
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
$0.87$1.04+$0.17$1.69$10.86 billion$10.85 billion
4/30/2026Q1 2026
Bristol Myers Squibb Company stock logo
BMY
Bristol Myers Squibb
$1.42$1.58+$0.16$1.31$10.93 billion$11.49 billion
4/30/2026Q1 2026
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$6.97$8.55+$1.58$8.26$17.82 billion$19.80 billion
3/31/2026Q1 2026
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
N/A$1.0270N/A$1.69N/A$10.85 billion
2/24/2026Q4 2025
Iovance Biotherapeutics, Inc. stock logo
IOVA
Iovance Biotherapeutics
-$0.22-$0.18+$0.04-$0.18$81.61 million$86.77 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Bristol Myers Squibb Company stock logo
BMY
Bristol Myers Squibb
$2.524.42%+1.61%70.79%17 Years
GSK PLC Sponsored ADR stock logo
GSK
GSK
$1.883.79%-7.86%48.83%N/A
ImmunoGen, Inc. stock logo
IMGN
ImmunoGen
N/AN/AN/AN/AN/A
Iovance Biotherapeutics, Inc. stock logo
IOVA
Iovance Biotherapeutics
N/AN/AN/AN/AN/A
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$6.920.69%+15.18%24.58%11 Years
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
$1.753.91%+21.74%41.08%N/A

Latest LLY, NVO, IMGN, GSK, BMY, and IOVA Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
4/29/2026
GSK PLC Sponsored ADR stock logo
GSK
GSK
quarterly$0.443.71%5/15/20265/15/20267/9/2026
5/4/2026
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
quarterly$1.730.69%5/15/20265/15/20266/10/2026
3/2/2026
Bristol Myers Squibb Company stock logo
BMY
Bristol Myers Squibb
quarterly$0.634.23%4/2/20264/2/20265/1/2026
1/1/2100
GSK PLC Sponsored ADR stock logo
GSK
GSK
quarterly$0.42064.3%8/15/20258/15/202510/9/2025
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Bristol Myers Squibb Company stock logo
BMY
Bristol Myers Squibb
2.10
1.42
1.28
GSK PLC Sponsored ADR stock logo
GSK
GSK
0.80
0.79
0.52
ImmunoGen, Inc. stock logo
IMGN
ImmunoGen
0.13
5.70
5.65
Iovance Biotherapeutics, Inc. stock logo
IOVA
Iovance Biotherapeutics
N/A
3.60
3.15
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
1.26
1.50
1.10
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
0.59
0.79
0.56

Institutional Ownership

CompanyInstitutional Ownership
Bristol Myers Squibb Company stock logo
BMY
Bristol Myers Squibb
76.41%
GSK PLC Sponsored ADR stock logo
GSK
GSK
15.74%
ImmunoGen, Inc. stock logo
IMGN
ImmunoGen
90.50%
Iovance Biotherapeutics, Inc. stock logo
IOVA
Iovance Biotherapeutics
77.03%
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
82.53%
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
11.54%
CompanyEmployeesShares OutstandingFree FloatOptionable
Bristol Myers Squibb Company stock logo
BMY
Bristol Myers Squibb
32,5002.04 billion2.04 billionOptionable
GSK PLC Sponsored ADR stock logo
GSK
GSK
66,8412.03 billion1.83 billionOptionable
ImmunoGen, Inc. stock logo
IMGN
ImmunoGen
277266.26 million252.76 millionNo Data
Iovance Biotherapeutics, Inc. stock logo
IOVA
Iovance Biotherapeutics
500446.50 million411.68 millionOptionable
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
50,000941.74 million940.42 millionOptionable
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
69,5054.47 billion4.46 billionOptionable

Recent News About These Companies

Buy, Sell, or Hold Novo Nordisk at $46?
Novo Nordisk: The First Fruits Of Labor
Best Healthcare Stocks to Buy in 2026
Novo Nordisk A/S (NVO) stock forecast and price target
Novo Nordisk: Why I Won't Upgrade
Omeros (OMER) Q1 2026 Earnings Transcript
Assorted pharmaceutical pills, a medicine vial, and a syringe arranged on a laboratory bench.
2 Ways to Play the Big Pharma Patent Cliff (NVO)
...

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Bristol Myers Squibb stock logo

Bristol Myers Squibb NYSE:BMY

$57.04 +0.27 (+0.47%)
Closing price 03:59 PM Eastern
Extended Trading
$56.76 -0.27 (-0.48%)
As of 04:46 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia. It also provides Yervoy for the treatment of patients with unresectable or metastatic melanoma; Empliciti for the treatment of multiple myeloma; Abecma for the treatment of relapsed or refractory multiple myeloma; Reblozyl for the treatment of anemia; Opdualag for the treatment of unresectable or metastatic melanoma; and Zeposia to treat relapsing forms of multiple sclerosis. In addition, the company offers Breyanzi for the treatment of relapsed or refractory large B-cell lymphoma; Onureg for the treatment of AML; Inrebic for the treatment of myelofibrosis; Camzyos for the treatment of symptomatic obstructive HCM to enhance functional capacity and symptom; Sotyktu for the treatment of moderate-to-severe plaque psoriasis; Augtyro for the treatment of locally advanced or metastatic ROS1-positive NSCLC; Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; and Abraxane to treat breast cancer, NSCLC and pancreatic cancer. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in Princeton, New Jersey.

GSK stock logo

GSK NYSE:GSK

$49.66 -1.30 (-2.55%)
Closing price 03:59 PM Eastern
Extended Trading
$49.72 +0.06 (+0.12%)
As of 04:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, flu, polio, influenza, and pandemic vaccines. It also provides medicines for HIV, oncology, respiratory/immunology, and other specialty medicine products, as well as inhaled medicines for asthma and chronic obstructive pulmonary disease, and antibiotics for infections. It has a collaboration agreement with CureVac to develop mRNA-based influenza vaccines, and with Wave Life Sciences and Elsie Biotechnologies, Inc for oligonucleotide platform development. The company was formerly known as GlaxoSmithKline plc and changed its name to GSK plc in May 2022. GSK plc was founded in 1715 and is headquartered in Brentford, the United Kingdom.

ImmunoGen stock logo

ImmunoGen NASDAQ:IMGN

ImmunoGen, Inc., a commercial-stage biotechnology company, focuses on developing and commercializing the antibody-drug conjugates (ADCs) for cancer patients. The company's product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha (FRa), for the treatment of platinum-resistant ovarian cancer; and a cell-surface protein expressed in various epithelial tumors, including ovarian, endometrial, and non-small-cell lung cancers, as well as Pivekimab sunirine, a CD123-targeting ADC that is in Phase II clinical trial for treating acute myeloid leukemia and blastic plasmacytoid dendritic cell neoplasm. Its preclinical programs include IMGC936, an ADC in co-development with MacroGenics, Inc.; and IMGN151, an anti-FRa product candidate. The company has collaborations with Roche; Amgen/Oxford BioTherapeutics; Bayer HealthCare AG; Eli Lilly and Company; Novartis Institutes for BioMedical Research, Inc.; CytomX Therapeutics, Inc.; Fusion Pharmaceuticals Inc.; Debiopharm International SA; and MacroGenics, Inc. ImmunoGen, Inc. was founded in 1980 and is headquartered in Waltham, Massachusetts. As of February 12, 2024, ImmunoGen, Inc. operates as a subsidiary of AbbVie Inc.

Iovance Biotherapeutics stock logo

Iovance Biotherapeutics NASDAQ:IOVA

$3.45 -0.07 (-1.99%)
Closing price 04:00 PM Eastern
Extended Trading
$3.46 +0.00 (+0.14%)
As of 04:49 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Iovance Biotherapeutics, Inc., a commercial-stage biotechnology company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the United States. The company offers Amtagvi, a tumor-derived autologous T cell immunotherapy used to treat adult patients with unresectable or metastatic melanoma; and Proleukin, an interleukin-2 product for the treatment of patients with metastatic renal cell carcinoma. It also develops lifileucel in combination with pembrolizumab to treat frontline advanced melanoma patients; LN-145 for the treatment of non-small cell lung cancer (NSCLC) and solid tumor cancers; IOV-4001, which is in Phase 1/2 IOV-GM1-201 clinical trial, for the treatment of NSCLC; and lifileucel for gynecological cancers. The company has collaborations and licensing agreements with WuXi Advanced Therapies, Inc.; National Institutes of Health; the National Cancer Institute; H. Lee Moffitt Cancer Center; The University of Texas M.D. Anderson Cancer Center; Cellectis S.A.; Novartis Pharma AG; and Boehringer Ingelheim Biopharmaceuticals GmbH. The company was formerly known as Lion Biotechnologies, Inc. and changed its name to Iovance Biotherapeutics, Inc. in June 2017. Iovance Biotherapeutics, Inc. was incorporated in 2007 and is headquartered in San Carlos, California.

Eli Lilly and Company stock logo

Eli Lilly and Company NYSE:LLY

$1,005.20 -1.51 (-0.15%)
Closing price 03:59 PM Eastern
Extended Trading
$1,003.70 -1.50 (-0.15%)
As of 04:52 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, including Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt, and Verzenio. In addition, the company offers Olumiant for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19; Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis; Omvoh for ulcerative colitis; Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Ebglyss for severe atopic dermatitis; and Emgality for migraine prevention and episodic cluster headache. Further, it provides Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. It has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; F. Hoffmann-La Roche Ltd and Genentech, Inc.; Biologics, Inc., AbCellera Biologics Inc.; and Chugai Pharmaceutical Co., Ltd. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.

Novo Nordisk A/S stock logo

Novo Nordisk A/S NYSE:NVO

$44.71 -1.09 (-2.38%)
Closing price 03:59 PM Eastern
Extended Trading
$44.46 -0.25 (-0.56%)
As of 04:53 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides insulin pens, growth hormone pens, and injection needles. In addition, it offers smart solutions for diabetes treatment, such as smart insulin pens and Dose Check, an insulin dose guidance application. The company has a collaboration agreement with Aspen Pharmaceuticals to produce insulin products; and with Korro Bio, Inc. for the discovery and development of new genetic medicines to treat cardiometabolic diseases. Novo Nordisk A/S was founded in 1923 and is headquartered in Bagsvaerd, Denmark.